Merck KGaA agrees to pay a 130% premium for Silence Therapeutics in $1.3 billion deal
The $20-per-ADS cash offer values Silence's equity at about $1.3 billion and centers on divesiran, an siRNA candidate for the rare blood cancer polycythemia vera. Closing is expected in the first quarter of 2027.

- Value
- $1.3B
- Type
- Acquisition
- Target
- Silence Therapeutics
- Buyer
- Merck KGaA, Darmstadt, Germany
- Sector
- Biotech
- Announced
- Oct. 19, 2026
In August, Silence Therapeutics sold new shares to the public at $13.50 per American depositary share. Two months later, Merck KGaA, Darmstadt, Germany, agreed to buy the whole company for $20 per ADS in cash.
Silence announced the deal Oct. 19. It values the RNA interference company's equity at about $1.3 billion, with an enterprise value of $1.1 billion. Each ADS represents three ordinary shares, so the offer works out to about $6.67 per share.
Silence said the price is a 130% premium to its ADS closing price on Oct. 16 and an 82% premium to the 30-day volume-weighted average price of $10.99. It is also about 48% above the $13.50 price of Silence's upsized $175 million offering, which the company priced Aug. 11.
Why it matters: The deal hands Merck KGaA a rare blood cancer candidate headed for Phase 3 development, according to Silence, and continues what Merck KGaA's chief executive described as a pipeline shift toward specialized medicines following the German company's purchase of SpringWorks Therapeutics last year. For investors who bought into Silence's August offering, it turns a $13.50 purchase into a $20 cash payout, if the deal closes.
Divesiran at the center
Silence develops short interfering RNA, or siRNA, medicines on a platform it calls mRNAi GOLD. Its wholly owned lead candidate, divesiran, is designed to switch off TMPRSS6, a gene expressed almost entirely in the liver. The aim is to raise levels of hepcidin, a hormone that regulates iron, and so curb the overproduction of red blood cells in polycythemia vera.
Polycythemia vera is a rare blood cancer in which the body makes too many red blood cells. Current care relies on repeated phlebotomies, or blood draws, drugs that slow the body's output of red cells, or both, according to Silence. Divesiran has FDA Fast Track and Orphan Drug designations for the condition.
Iain Ross, Silence's chairman and interim principal executive officer, said the agreement was "the result of a competitive sale process." He said it follows Phase 2 data in polycythemia vera and puts divesiran with a buyer big enough to speed its Phase 3 development.
Kai Beckmann, chairman of the executive board and group chief executive of Merck KGaA, Darmstadt, Germany, said the acquisition "will strengthen our capabilities to serve patients with targeted specialty and rare diseases." He said the company is shifting its pipeline toward highly specialized areas and counts M&A among its strategic priorities.
Merck KGaA, Darmstadt, Germany, reported sales of 21.1 billion euros in 2025, according to the release. In the U.S. and Canada, its healthcare business operates as EMD Serono.
How the deal closes
The acquisition will be carried out through a U.K. scheme of arrangement. It needs approval from Silence shareholders, sanction by the High Court of Justice of England and Wales and regulatory approvals.
Silence's board approved the deal unanimously, and holders of about 14% of its voting rights have agreed to back the deal, the company said. Morgan Stanley and Centerview Partners are Silence's financial advisers, and Cooley is its legal counsel.
The companies expect to close in the first quarter of 2027. Neither source said how Merck KGaA will pay for the deal, and the announcement did not set a timeline for starting Phase 3 trials of divesiran.



